Abstract
AN indirect estimate of monoamine oxidase (MAO) activity based on the formation of 14C-5-hydroxyindoleacetic acid from intravenously administered 14C-serotonin revealed no differences between schizophrenic patients and controls1. The important regulatory functions of monoamine oxidase in biogenic amine metabolism2, together with the evidence that MAO-inhibiting drugs may on occasion contribute to exacerbations of psychotic behaviour3, suggested, however, that direct examination of cellular MAO in schizophrenic patients might be of interest.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Feldstein, A., Hoagland, H., and Freeman, H., Arch. Gen. Psychiat., 5, 246 (1961).
Kopin, I. J., Pharmacol. Rev., 16, 179 (1964).
Crane, G. E., J. Nerv. Ment. Disorders, 124, 322 (1956).
Robinson, D. S., Lovenberg, W., Keiser, H., and Sjoerdsma, A., Biochem. Pharmacol., 17, 109 (1968).
Collins, G. G. S., Sandler, M., Williams, E. D., and Youdim, M. B. H., Nature, 225, 817 (1970).
Collins, G. G. S., and Sandler, M., Biochem. Pharmacol., 20, 289 (1971).
Murphy, D. L., and Weiss, R., Amer. J. Psychiat. (in the press).
Murphy, D. L., Colburn, R. W., Davis, J. M., and Bunney, jun., W. E., Life Sci., 8, 1187 (1969).
Wurtman, R. J., and Axelrod, J., Biochem. Pharmacol., 12, 1439 (1963).
DSM-II, Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, Washington, DC, 1968).
Wyatt, R. J., Termini, B. A., and Davis, J., Schiz. Bull., 4, 10 (1971).
Ehringer, H., and Lechner, K., Naunyn Schmiedeberg Arch. Pharm., 239, 507 (1960).
Harker, L. A., and Finch, C. A., J. Clin. Invest., 48, 963 (1969).
Wurtman, R. J., and Axelrod, J., Biochem. Pharmacol., 12, 1417 (1963).
Eleftheriou, B. E., and Boehlke, K. W., Science, 155, 1693 (1967).
Reis, D. J., Moorhead, D. T., II, Rifkin, M., Joh, T., and Goldstein, M., Fed. Proc., 29, 277 (1970).
Akindele, M. O., Evans, J. I., and Oswald, D., Electroenceph. Clin. Neurophysiol., 29, 47 (1970).
Rees, L., and Benaim, S., J. Ment. Sci., 106, 193 (1960).
Pollin, W., Cardon, jun., P. V., and Kety, S. S., Science, 133, 104 (1961).
Berlet, H. H., Matsumoto, K., Pscheidt, G. R., Spaide, J., Bull, C., and Himwich, H. E., Arch. Gen. Psychiat., 13, 521 (1965).
Southgate, J., and Collins, G. G. S., Biochem. Pharmacol., 18, 2285 (1969).
Jarrot, B., J. Neurochem., 18, 7 (1971).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
MURPHY, D., WYATT, R. Reduced Monoamine Oxidase Activity in Blood Platelets from Schizophrenic Patients. Nature 238, 225–226 (1972). https://doi.org/10.1038/238225a0
Received:
Issue Date:
DOI: https://doi.org/10.1038/238225a0
This article is cited by
-
Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson’s Disease
Neurochemical Research (2009)
-
Microarray Analysis of Differentially Expressed Genes in Rat Frontal Cortex Under Chronic Risperidone Treatment
Neuropsychopharmacology (2005)
-
Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia
Psychopharmacology (1995)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
